1.
Histone methyltransferase inhibitors induce HIV-1 recovery in resting CD4+ T cells from HIV-1-infected HAART-treated patients
by BOUCHAT, Sophie
AIDS (London), 2012, Vol.26 (12), p.1473-1482
2.
Level of double negative T cells, which produce TGF-β and IL-10, predicts CD8 T-cell activation in primary HIV-1 infection
by PETITJEAN, Gaël
AIDS (London), 2012, Vol.26 (2), p.139-148
3.
Global and regional molecular epidemiology of HIV-1, 1990–2015: a systematic review, global survey, and trend analysis
by Hemelaar, Joris
The Lancet infectious diseases, 2018-11
4.
The effect of HAART-induced HIV suppression on circulating markers of inflammation and immune activation
by Wada, Nikolas Itaru
AIDS (London), 2015-02-20, Vol.29 (4), p.463-471
5.
Epitope-based vaccine design yields fusion peptide-directed antibodies that neutralize diverse strains of HIV-1
by Xu, Kai
Nature medicine, 2018-06, Vol.24 (6), p.857-867
6.
Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection
by HRABER, Peter
AIDS (London), 2014, Vol.28 (2), p.163-169
7.
Structural definition of a conserved neutralization epitope on HIV-1 gp120
by Van Ryk, Donald
Nature, 2007-02-15, Vol.445 (7129), p.732-737
8.
Natural Killer cells in HIV-1 infection and therapy
by Mikulak, Joanna
AIDS (London), 2017-09-18, Vol.31 (17), p.2317-2330
9.
Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape
by Moore, Penny L
Nature medicine, 2012-11, Vol.18 (11), p.1688-1692
10.
In-depth determination and analysis of the human paired heavy- and light-chain antibody repertoire
by DeKosky, Brandon J
Nature medicine, 2015-01, Vol.21 (1), p.86-91
11.
Antibody 10-1074 suppresses viremia in HIV-1-infected individuals
by Caskey, Marina
Nature medicine, 2017-02, Vol.23 (2), p.185-191
12.
The effect of oral preexposure prophylaxis on the progression of HIV-1 seroconversion
by Donnell, Deborah
AIDS (London), 2017-09-10, Vol.31 (14), p.2007-2016
13.
Viral variants that initiate and drive maturation of V1V2-directed HIV-1 broadly neutralizing antibodies
by Bhiman, Jinal N
Nature medicine, 2015-11, Vol.21 (11), p.1332-1336
14.
HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation
by Sékaly, Rafick-Pierre
Nature medicine, 2009-08, Vol.15 (8), p.893-900
15.
Challenges in the development of an HIV-1 vaccine
by Barouch, Dan H
Nature, 2008-10-02, Vol.455 (7213), p.613-619
16.
Monocyte chemoattractant protein-1 (MCP-1): an overview
by Deshmane, Satish L
Journal of interferon & cytokine research, 2009-06, Vol.29 (6), p.313-326
17.
COMPASS identifies T-cell subsets correlated with clinical outcomes
by Lin, Lin
Nature biotechnology, 2015-06, Vol.33 (6), p.610-616
18.
HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects
by Buzón, Maria J
Nature medicine, 2010-04, Vol.16 (4), p.460-465
19.
The Immune Response to Mycobacterium tuberculosis in HIV-1-Coinfected Persons
by Esmail, Hanif
Annual review of immunology, 2018-04-26, Vol.36 (1), p.603-638
20.
Early short-term treatment with neutralizing human monoclonal antibodies halts SHIV infection in infant macaques
by Hessell, Ann J
Nature medicine, 2016-04, Vol.22 (4), p.362-368
